Promising phase II biologics for future Crohn's disease therapy.

Wils, Pauline; Danese, Silvio; Peyrin-Biroulet, Laurent

Document type :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1080/13543784.2023.2219386

PMID :

37249522

Permalink :

http://hdl.handle.net/20.500.12210/105686

Title :

Promising phase II biologics for future Crohn's disease therapy.

Author(s) :

Wils, Pauline [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Danese, Silvio [Auteur]
IRCCS Ospedale San Raffaele [Milan, Italy]
Peyrin-Biroulet, Laurent [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]

Journal title :

Expert Opinion on Investigational Drugs

Abbreviated title :

Expert Opin Investig Drugs

Pages :

1-13

Publication date :

2023-06-04

ISSN :

1744-7658

English keyword(s) :

biologics
Crohn's disease
inflammatory bowel diseases
Phase II
randomized trials

English abstract : [en]

Introduction Although the physician’s therapeutic arsenal of Crohn’s Disease (CD) is rapidly expanded over the next 25 years, a significant proportion of patients remain non-responders, or develop a loss of response or ...
Show more >Introduction Although the physician’s therapeutic arsenal of Crohn’s Disease (CD) is rapidly expanded over the next 25 years, a significant proportion of patients remain non-responders, or develop a loss of response or intolerance to current therapies, indicating a need for new therapeutic strategies in CD. Areas covered This review examines the efficacy and safety data from phase II clinical trials on biologics, performed in patients with moderate-to-severe CD. A PubMed database literature review was conducted for relevant articles published from 2017 to 2022. Ongoing clinical phase II trials were retrieved from ClinicalTrials.gov database or abstracts from major congresses. Future perspectives for the treatment of CD patients with these new molecules were also discussed. Expert opinion Among the most promising biologics are interleukin (IL)-23p19 inhibitors (guselkumab, mirikizumab, and brazikumab), IL-6 inhibitors, and anti-adhesion molecules (ontamalimab). Furthermore, multiple biologics with different mechanisms of action are in clinical development for moderate-to-severe CD including molecules with anti-fibrotic mechanism of action (anti-TL1A, anti-IL-36 receptor). In addition to efficacy, some of them provide reassuring safety profiles. Phase III trials need to confirm these results, especially on their long-term safety issues.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-02-01T22:05:45Z
2024-03-11T15:54:19Z

Version	Link	Modification date
2	20.500.12210/105686*	2024-03-11T15:52:06Z
1	20.500.12210/105686.1	2024-02-01T22:05:45Z

Promising phase II biologics for future ...

BibTeX

CSV

Excel

RIS

Version history

Promising phase II biologics for future ... BibTeX CSV Excel RIS

Version history

Promising phase II biologics for future ...

BibTeX

CSV

Excel

RIS